Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Senkus, Elżbieta; Kyriakides, S.; Ohno, Shinji; Penault‐Llorca, Frédérique; Poortmans, Philip; Rutgers, E.; Zackrisson, Sophia; Cardoso, Fátima

doi:10.1093/annonc/mdv298

Cited by 1,319 publications

(1,137 citation statements)

References 148 publications

Supporting

Mentioning

1,059

Contrasting

Unclassified

Order By: Relevance

“…The European Society for Medical Oncology recommends that breast cancer treatment should be carried out in ‘breast units’ by multidisciplinary teams of oncologists, surgeons, radiologists, pathologists and, where appropriate, reconstructive surgeons and psychologists [11]. While these conditions may not exist in low- and middle-income countries, they represent a benchmark of best practice.…”

Section: Discussionmentioning

confidence: 99%

“…We extracted relevant details (including contextual information such as socio-economic data, demographics and incidence rates) and charted them to assist with our analysis of the findings. We consulted international guidelines from the WHO [9], the Breast Health Global Initiative (BHGI) [10], the European Society for Medical Oncology [11], the Asian Oncology Summit [12] and key articles in journals on global surgery and cancer control in low- and middle-income countries [13,14]. We compared recommendations from the guidelines with the results from our review, and by identifying discrepancies and gaps we sought to make recommendations for future areas of focus to strengthen Vietnam’s response to breast cancer.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Breast cancer services in Vietnam: a scoping review

Jenkins

Minh

Anh

et al. 2018

Global Health Action

View full text Add to dashboard Cite

Background: Breast cancer incidence has been increasing consistently in Vietnam. Thus far, there have been no analytical reviews of research produced within this area. Objectives: We sought to analyse the nature andextent of empirical studies about breast cancer in Vietnam, identifying areas for future research and systemsstrengthening. Methods: We undertook a scoping study using a five-stage framework to review published and grey literature in English and Vietnamese on breast cancer detection, diagnosis and treatment. We focused specifically on research discussing the health system and service provision. Results: Our results show that breast cancer screening is limited, with no permanent or integrated national screening activities. There is a lack of information on screening processes and on the integration of screening services with other areas of the health system. Treatment is largely centralised, and across all services there is a lack of evaluation and data collection that would be informative for recommendations seeking to improve accessibility and quality of breast cancer services. Conclusions: This paper is the first scoping review of breast cancer services in Vietnam. It outlines areas for future focus for policy makers and researchers with the objective of strengthening service provision to women with breast cancer across the country while also providing a methodological example for how to conduct a collaborative scoping review.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Breast cancer services in Vietnam: a scoping review

Jenkins

Minh

Anh

et al. 2018

Global Health Action

View full text Add to dashboard Cite

show abstract

“…Trastuzumab is an established treatment option for patients with HER2 + breast cancer [9,14,15,17] and HER2 + gastric and gastroesophageal junction cancer [19][20][21]. In clinical trials, trastuzumab is associated with increased pathological complete response rates and eventfree survival rates when used as part of a neoadjuvant treatment regimen in early HER2 + breast cancer [31][32][33], and increased rates of disease-free and overall survival rates when used as a component of adjuvant treatment [10,34,35].…”

Section: Discussionmentioning

confidence: 99%

“…Originator or 'reference' trastuzumab (Herceptin ® ) is approved for the adjuvant treatment of HER2-positive (HER2 +) breast cancer, the treatment of HER2 + metastatic breast cancer (MBC) and HER2 + metastatic gastric or gastroesophageal junction adenocarcinoma in the USA [7], and of HER2 + MBC, HER2 + early breast cancer (EBC) and HER2 + metastatic gastric or gastroesophageal junction adenocarcinoma in Europe [8]. The combination of reference trastuzumab with chemotherapy in HER2 + breast cancer has been shown to improve response rates, reduce recurrence risk and increase survival, compared with chemotherapy alone [9][10][11][12][13], findings that support the inclusion of this approach in European [9,14] and USA [15][16][17] treatment guidelines. Such combination therapy also increases survival, compared with chemotherapy alone, in advanced HER2 + gastric or gastroesophageal junction cancers [18], as reflected in clinical guidelines [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab

Esteva¹,

Stebbing

Wood-Horrall³

et al. 2018

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose Access to trastuzumab, a valuable anti-cancer treatment, can be limited by cost. The primary aim of this study was to evaluate and compare the PK profiles of CT-P6, a biosimilar of trastuzumab, and US-licensed reference trastuzumab (Herceptin ® ) in healthy subjects. Secondary study aims included comparison of the safety and immunogenicity of CT-P6 and reference trastuzumab in these subjects. Methods We performed a single-dose, randomised, double-blind, parallel group study (NCT02665637) comparing CT-P6 with reference trastuzumab (6 mg/kg, 90 min intravenous infusion) in 70 healthy adult males. Pharmacokinetics, safety and immunogenicity were evaluated up to 10 weeks post-dose. Primary endpoints were area under the serum concentration-time curve (AUC) from time 0 to infinity (AUC inf ); AUC from time 0 to last quantifiable concentration (AUC last ); and observed maximum serum concentration (C max ). The pre-determined equivalence criterion was a 90% confidence interval of 80-125% for ratios of geometric least squares (LS) means. Results Equivalence of CT-P6 and reference trastuzumab was demonstrated. Ratios (CT-P6/reference trastuzumab) of geometric LS means (90% confidence interval) were: AUC inf 99.05 (93.00, 105.51); AUC last 99.30 (92.85, 106.20); C max 96.58 (90.93, 102.59). Safety profiles were similar; treatment-emergent adverse events occurred in ten subjects (28.6%) in the CT-P6 group and 11 (31.4%) in the reference trastuzumab group. No serious adverse events or deaths occurred. No subjects tested positive for anti-drug antibodies. Conclusions These data add to the totality of evidence required to demonstrate biosimilarity. A phase III study of CT-P6-in which equivalent neoadjuvant efficacy to reference trastuzumab has been demonstrated-is ongoing.

show abstract

“…Breast cancer is the most common malignant disease among women and a major cause of cancer‐related mortality in the developed world (Senkus et al ., 2015; Siegel et al ., 2016). Breast cancer heterogeneity resulting in variable therapy response and survival emphasizes the need for novel diagnostic, prognostic and predictive markers regulating different aspects of tumour cell behaviour in order to improve disease management (Lastraioli et al ., 2015).…”

Section: Introductionmentioning

confidence: 99%

SK4 channels modulate Ca²⁺ signalling and cell cycle progression in murine breast cancer

et al. 2017

View full text Add to dashboard Cite

Oncogenic signalling via Ca2+‐activated K+ channels of intermediate conductance (SK4, also known as KCa3.1 or IK) has been implicated in different cancer entities including breast cancer. Yet, the role of endogenous SK4 channels for tumorigenesis is unclear. Herein, we generated SK4‐negative tumours by crossing SK4‐deficient (SK4 KO) mice to the polyoma middle T‐antigen (PyMT) and epidermal growth factor receptor 2 (cNeu) breast cancer models in which oncogene expression is driven by the retroviral promoter MMTV. Survival parameters and tumour progression were studied in cancer‐prone SK4 KO in comparison with wild‐type (WT) mice and in a syngeneic orthotopic mouse model following transplantation of SK4‐negative or WT tumour cells. SK4 activity was modulated by genetic or pharmacological means using the SK4 inhibitor TRAM‐34 in order to establish the role of breast tumour SK4 for cell growth, electrophysiological signalling, and [Ca2+]i oscillations. Ablation of SK4 and TRAM‐34 treatment reduced the SK4‐generated current fraction, growth factor‐dependent Ca2+ entry, cell cycle progression and the proliferation rate of MMTV‐PyMT tumour cells. In vivo, PyMT oncogene‐driven tumorigenesis was only marginally affected by the global lack of SK4, whereas tumour progression was significantly delayed after orthotopic implantation of MMTV‐PyMT SK4 KO breast tumour cells. However, overall survival and progression‐free survival time in the MMTV‐cNeu mouse model were significantly extended in the absence of SK4. Collectively, our data from murine breast cancer models indicate that SK4 activity is crucial for cell cycle control. Thus, the modulation of this channel should be further investigated towards a potential improvement of existing antitumour strategies in human breast cancer.

show abstract

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 1,319 publications

References 148 publications

Breast cancer services in Vietnam: a scoping review

Breast cancer services in Vietnam: a scoping review

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab

SK4 channels modulate Ca²⁺ signalling and cell cycle progression in murine breast cancer

Contact Info

Product

Resources

About

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 1,319 publications

References 148 publications

Breast cancer services in Vietnam: a scoping review

Breast cancer services in Vietnam: a scoping review

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab

SK4 channels modulate Ca2+ signalling and cell cycle progression in murine breast cancer

Contact Info

Product

Resources

About

SK4 channels modulate Ca²⁺ signalling and cell cycle progression in murine breast cancer